Follow Us:

FSG Blogs

see all

Global Health Blog RSS

See more posts from the Global Health blog

This blog contains posts from the Global Health impact area at FSG.
Posted by: Chris Carlson on 1/12/2015

Historically, non-communicable diseases (NCDs) have not enjoyed a high profile in global health circles and popular media alongside their communicable brethren such as HIV, malaria, TB, and Ebola, but there is much reason to believe this is changing. Even amid the Ebola crisis, 2014 was a year of increased global focus on addressing the expanding burden of NCDs and their effects in low and middle income countries. This intensity has been reflected in a range of important work, including:

Posted by: Alex Geertz on 10/2/2014

Several threads in the news lately connect to how health systems pivot from crisis mode to a sustained response. The countries affected by the Ebola epidemic are moving from an initial influx of technical advisers to emphasize longer-term strengthening of their health systems. Funders like The Global Fund to Fight AIDS, Tuberculosis and Malaria are adopting new mechanisms to address countries in transition from donor dependence to country ownership.

Posted by: FSG on 2/13/2014

Read What Is the Social Value of Pharmaceuticals?

This post by Sebastien Mazurri shares highlights from a recent Twitter Chat hosted by The Guardian Sustainable Business Pharma Futures Blog.

Posted by: Rebecca Weissburg on 2/11/2014

The announcement that CVS will no longer sell tobacco products in its U.S. stores is welcome news to many public health practitioners and advocates. Lung cancer is the leading cancer killer in the United States, causing more deaths than the next three most common cancers combined. And although U.S. smoking rates have never been lower and continue to decline, the number of deaths due to lung cancer in the United States grew by 4.3% between 1999 and 2008.

Posted by: Simon Meier on 1/9/2014

Why drugs are so expensive: It's the science, stupid

In a new blog series from Scientific American discussing the challenges of drug discovery, chemist Ashutosh Jogalekar explains why the process is so expensive. According to Jogalekar, a main reason for the high costs is the complexity of biology.

1 2 3 4 5 6 7 8 9 10  ...  Go to Page:

Follow Us:

Facebook Twitter YouTube LinkedIn RSS